Welcome to our dedicated page for ANI PHARMACEUTICALS SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ANI PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ANI PHARMACEUTICALS's regulatory disclosures and financial reporting.
ANI Pharmaceuticals director Matthew J. Leonard reported the sale of 6,937 shares of ANIP common stock on 08/18/2025. The shares were sold in multiple trades at prices ranging from $87.66 to $88.36, with a weighted-average sale price of $88.17. After the transactions Mr. Leonard beneficially owned 9,392 shares, reported as directly owned. The Form 4 was filed as a single reporting person filing and is signed by an attorney-in-fact on behalf of Mr. Leonard.
This filing documents a routine insider disposition of equity by a director and provides the exact sale quantity, price range, weighted-average price, and resulting beneficial ownership shown on the Form 4.
Insider sale reported: ANI Pharmaceuticals director Patrick D. Walsh disposed of 9,000 shares of ANIP common stock on 08/15/2025 at $89.05 per share, according to this Form 4. After the sale he beneficially owned 70,048 shares. The form was signed by an attorney-in-fact on 08/18/2025. No derivative transactions or additional explanations are disclosed.
ANI Pharmaceuticals insider sales by Shanmugam Muthusamy The filing shows that Shanmugam Muthusamy, a director and an officer (Head of R&D, COO-Novitium Ops), reported sales of ANI Pharmaceuticals (ANIP) common stock on 08/14/2025 and 08/15/2025. On 08/14/2025 he sold 47,010 shares at a weighted average price of $89.48, leaving 584,910 shares reported as beneficially owned through Esjay LLC. On 08/15/2025 he sold 52,990 shares at a weighted average price of $87.15, leaving 531,920 shares reported as beneficially owned through Esjay LLC. The filing also reports indirect ownership of 5,000 shares held by SS Pharma LLC. The statement is signed by attorney-in-fact Meredith W. Cook on 08/18/2025.
ANI Pharmaceuticals insider sale reported. Chad Gassert, SVP - Corporate Development & Strategy, reported a disposition of 20,000 shares of ANI Pharmaceuticals common stock on 08/15/2025 at a weighted-average price of $86.97 per share. Following the reported transactions, the reporting person beneficially owns 173,226 shares indirectly through Chali Properties LLC, over which he holds voting and dispositive power.
The filing clarifies the sale was executed in multiple trades at prices ranging from $86.54 to $88.05. The form is signed by an attorney-in-fact on behalf of Mr. Gassert and lists his role with the company as an officer.
ANI Pharmaceuticals, Inc. (ANIP) Form 144 reports a proposed sale of 6,865 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $616,223.68. The filing lists the approximate number of shares outstanding as 21,688,772 and an approximate sale date of 08/18/2025 on NASDAQ.
The shares were acquired on 05/23/2024 as restricted stock from the issuer, with payment recorded on the same date. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that they do not possess undisclosed material adverse information.
ANI Pharmaceuticals (ANIP) Form 144 notice discloses a proposed sale of 6,937 common shares held by an insider through Morgan Stanley Smith Barney LLC, with an aggregate market value of $611,644.31 based on the filing. The shares represent a small portion of the company's outstanding common stock (21,688,772 shares outstanding) and the proposed sale is slated to occur on 08/18/2025 on NASDAQ.
The filing also lists the acquisition history for the shares being offered: 2,527 restricted shares acquired on 08/21/2024 and 4,410 restricted shares acquired on 05/21/2025, both issued by the company. No securities were reported sold by the person in the prior three months on this form, and the filer certifies that they have no undisclosed material adverse information.
ANI Pharmaceuticals (ANIP) Form 144 notice reports a proposed sale of 29,580 common shares through Morgan Stanley Smith Barney on 08/18/2025, with an aggregate market value of $2,612,419.82 and total shares outstanding listed as 21,688,772. The filer acquired these shares on 11/19/2021 as convertible preferred shares from the issuer and paid in cash. The filing also discloses a recent sale of 91,000 shares on 08/15/2025 generating $7,866,267.50. The notice includes the standard representation that the seller is unaware of undisclosed material adverse information.
ANI Pharmaceuticals, Inc. (ANIP) submitted a Form 144 notifying the proposed sale of 9,000 shares of common stock via Morgan Stanley Smith Barney LLC on 08/15/2025. The filing lists an aggregate market value of $801,450.00 for those shares and reports 21,688,772 shares outstanding for the issuer. The 9,000 shares were acquired from the issuer as restricted stock on 03/23/2022, and no securities were reported sold by the seller in the past three months. The notice includes the required representation that the selling person is not aware of undisclosed material adverse information.
ANI Pharmaceuticals (ANIP) filed a Form 144 proposing the sale of 91,000 common shares. The shares are scheduled for an approximate sale date of 08/15/2025 through Morgan Stanley Smith Barney LLC and carry an aggregate market value of $7,866,267.50. The filing reports 21,688,772 shares outstanding, meaning the proposed sale represents a small fraction of total shares. The 91,000 shares were acquired on 11/19/2021 in exchange for convertible preferred shares and were paid for in cash on the acquisition date. No other sales in the prior three months were reported.
ANI Pharmaceuticals (ANIP) Form 144 notice discloses a proposed sale of 52,990 common shares through Merrill Lynch on NASDAQ with an aggregate market value of $4,618,063.56, and reports 21,688,772 shares outstanding. The filer indicates the shares were acquired on 11/19/2021 via a company buyout and are being sold as a compensatory payment. The filing also lists a recent sale by the same person: 47,010 common shares sold on 08/14/2025 for gross proceeds of $4,206,603.82. The notice includes the seller’s representation that they are not aware of undisclosed material adverse information about the issuer.